Uncategorized
JCRS Publication of Phase II Nepafenac Clinical Trial With Evolute® Sustained Drug Delivery System Demonstrates Significant Post-Op Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that a peer reviewed manuscript of a Phase II clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute® sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery. The trial is a multi-center, randomized, masked evaluation of Nepafenac vs. placebo in 56 patients undergoing cataract surgery. The primary endpoint was to